When to take tesamorelin: timing, cycle length, and dosing

Last updated 2026-07-24

What time of day should you take tesamorelin?

The phase 3 trials that led to FDA approval of tesamorelin (brand name Egrifta) dosed it once daily, and most clinical guidance recommends evening administration, roughly 30 minutes before eating dinner or at bedtime on an empty stomach. This mirrors the body's natural growth hormone release pattern, which peaks during early sleep, and avoids the blunting effect that a recent meal, especially one high in carbohydrate or fat, can have on GHRH-stimulated GH release. The pooled phase 3 analysis of two multicenter, double-blind, placebo-controlled trials used a fixed once-daily subcutaneous dose and tracked outcomes over 26 weeks with a safety extension beyond that . Nothing in that dataset compared morning versus evening dosing head to head. The evening recommendation comes from GH physiology and manufacturer labeling conventions, not a dedicated timing trial. If you're on a provider-reviewed protocol, follow the specific timing in your prescription. For most people that means the same time every night, seven nights a week, not a schedule that shifts around meals or workouts. See tesamorelin dosage for the full mg-per-day breakdown and how it's built up over time.

Should you take tesamorelin on an empty stomach?

Yes. The standard instruction is to inject at least 30 minutes before eating, because circulating glucose and insulin blunt the GH pulse that GHRH analogues are designed to trigger. This isn't unique to tesamorelin; it's basic GH axis physiology covered in reviews of GHRH-releasing factor analogues . In practice this means no dinner right before the shot, and ideally nothing more than a small snack in the hour prior. It doesn't need to be a full overnight fast. The goal is just to avoid a large glucose spike competing with the drug at the moment it's trying to stimulate pituitary GH release. Patients on a stable evening routine (same time, same fasted state) tend to report the most consistent experience, though there's no trial data comparing fasted versus fed dosing directly in tesamorelin's own studies.

How long does a tesamorelin cycle actually last?

In the phase 3 program that supported FDA approval, tesamorelin was studied over a 26-week primary treatment period, with an extension phase evaluating continued use beyond six months . That's the evidence base behind its approved indication: reduction of excess visceral adipose tissue in HIV-associated lipodystrophy. There's no FDA-specified maximum treatment duration and no validated "cycle off, cycle back on" protocol. What the data does show is that visceral fat reduction is not necessarily durable after stopping. Discontinuation trials and clinical reviews of tesamorelin in HIV-associated lipodystrophy note that visceral adipose tissue tends to re-accumulate once treatment stops, which is consistent with how GH-axis therapies generally behave once the stimulus is withdrawn ^[1]. This matters for anyone thinking about a fixed "12 week cycle then break" plan borrowed from bodybuilding forums. That structure isn't what was tested. The approved use is continuous daily dosing evaluated over roughly six months and beyond, not a pulsed cycle.

What is tesamorelin actually approved to treat?

Tesamorelin (Egrifta) is FDA-approved specifically to reduce excess visceral adipose tissue (VAT) in adults with HIV-associated lipodystrophy. This is a narrow indication tied to a specific patient population and a specific fat compartment, not a general fat-loss or anti-aging approval. The approval rests on real phase 3 evidence. The pooled analysis of two multicenter trials showed measurable VAT reduction with tesamorelin versus placebo over 26 weeks, along with safety extension data . A 2026 meta-analysis of randomized controlled trials pooling tesamorelin outcomes in HIV-associated lipodystrophy reported effects on body composition, hepatic fat, and metabolic parameters, matching the visceral fat and liver fat signal seen across the individual trials ^[2]. Beyond the label, researchers have also looked at liver fat specifically. A randomized, double-blind, multicentre trial found tesamorelin reduced hepatic fat fraction in people with HIV and NAFLD , and transcriptomic work has tried to map the biological pathways behind that hepatic effect ^[3]. None of this changes the label. Tesamorelin's FDA approval covers visceral fat reduction in HIV-associated lipodystrophy; everything else, including any general aesthetic use, is off-label and not what the phase 3 program tested for.

Can you take tesamorelin if you don't have HIV-associated lipodystrophy?

People do take it off-label, most often for visceral fat reduction or general growth hormone support, but this sits entirely outside the FDA-approved use. Off-label prescribing is legal and common in medicine generally, but it means the specific trial evidence backing tesamorelin's approval doesn't automatically transfer to a different population. A 2024 study looked at tesamorelin's efficacy and safety in people with HIV who were on integrase inhibitor-based antiretroviral regimens specifically, since that combination wasn't well represented in the original approval trials ^[4]. That's a useful gap-filling study, but it's still within the HIV population, not a general metabolic health cohort. Broader reviews of peptide therapies in orthopaedic and sports medicine settings have started cataloguing tesamorelin alongside other GH-axis peptides used off-label for musculoskeletal or performance goals, but these reviews are explicit that formal efficacy and safety data in those populations is limited ^[5][6][7]. If you're considering tesamorelin outside the approved indication, that's a conversation to have directly with a prescriber who can walk you through what is and isn't established, not something to self-direct off internet routines.

How is tesamorelin injected, and does injection site matter for timing?

Tesamorelin is given as a subcutaneous injection, typically into the abdomen, with rotation of injection sites recommended to avoid lipohypertrophy or local skin changes at any single spot. It's supplied as a lyophilized powder that has to be reconstituted before use, and reconstituted solution has a limited use window, which is one reason daily dosing routines matter for both efficacy and product handling. Injection site itself hasn't been shown to change how the timing recommendation works; the evening, before-meal instruction applies regardless of which abdominal quadrant you use that day. What does matter is consistency of technique and storage, since a mishandled reconstitution can affect potency independent of when in the day you inject. For a full walkthrough of mixing bacteriostatic water ratios, storage temperatures, and use windows, see tesamorelin reconstitution.

Does the pharmacokinetic profile explain the once-daily schedule?

Yes, in part. A population pharmacokinetic analysis of tesamorelin in both HIV-infected patients and healthy subjects modeled how the drug is absorbed and cleared after subcutaneous dosing, supporting the once-daily regimen used in the approved product . Tesamorelin has a short half-life typical of peptide GHRH analogues, meaning it doesn't linger in circulation, which is exactly why timing (an evening dose ahead of the nocturnal GH pulse) is built into how it's supposed to be used rather than an arbitrary habit. This short-half-life, once-daily design is also why missed-dose handling is simple in principle: you don't stack doses to catch up, you just resume the schedule the next evening. There's no published tesamorelin trial data on double-dosing or make-up dosing, so the safe assumption is to skip a missed dose rather than compensate.

What happens if you take tesamorelin at the wrong time or inconsistently?

Nobody has a trial specifically testing inconsistent or mistimed tesamorelin dosing, so this is inference from GH-axis physiology and general peptide pharmacology, not a direct citation. Taking it after a large meal likely blunts the GH pulse it's meant to trigger, since insulin and glucose suppress GHRH-stimulated GH release, a well-established physiological interaction referenced in reviews of GH-releasing factor analogues . Erratic timing, skipping several days here and there, is also unlikely to replicate the steady, once-daily dosing pattern used in the phase 3 trials that generated the approval data . Trial results reflect a consistent daily regimen over 26 weeks; an on-again-off-again pattern is a different exposure than what was studied, and there's no dataset describing what partial adherence does to visceral fat outcomes. The practical takeaway: same time nightly, mostly fasted, don't skip stretches and expect the same result as continuous dosing.

Does tesamorelin need to be taken with any other medication or supplement?

No co-administration is required by the FDA label, and there's no trial evidence that pairing tesamorelin with another supplement changes its effect on visceral fat. Reviews covering peptide use in aesthetic, metabolic, and endocrine contexts discuss tesamorelin alongside other GH-axis compounds, but describe it as used on its own in the approved indication rather than as part of a stack ^[8]. Some off-label protocols pair GHRH analogues with GH secretagogues or other peptides on the theory of amplifying pulsatile GH release. That combination hasn't been tested in tesamorelin's own randomized trials, so any claimed benefit is theoretical, not evidence-based. If a provider suggests combining it with something else, ask specifically what data supports that combination, because the phase 3 program behind tesamorelin's approval evaluated it as monotherapy .

How does timing interact with tesamorelin's known side effects?

Injection site reactions, joint pain, swelling (edema), and paresthesia are among the most commonly reported adverse events in tesamorelin trials, largely tied to the GH-elevation mechanism itself rather than time of day. The pooled phase 3 safety data, including the extension phase, characterized these effects over sustained daily use , and reviews of tesamorelin's pharmacology and safety in HIV-associated lipodystrophy describe similar patterns ^[9][10]. Evening dosing doesn't meaningfully change which side effects occur, but a consistent nightly schedule does make it easier to notice a change if one shows up, like new joint discomfort or fluid retention, because you're comparing similar conditions night to night rather than a moving target. For the full rundown of what to expect and how common each effect is, see tesamorelin peptide side effects.

Where does tesamorelin fit if you're weighing it against other options?

Tesamorelin's strongest asset is that it's an FDA-approved drug (Egrifta) with real phase 3 trial data specifically for visceral fat reduction in HIV-associated lipodystrophy, not a compounded or unapproved peptide riding on general GH-axis theory. That distinction matters a lot when you're comparing it to other GHRH analogues or GH secretagogues that haven't gone through the same regulatory bar. Under federal compounding law, tesamorelin as an active pharmaceutical ingredient sits within FDA's bulk drug substance frameworks for section 503A and 503B compounding , which is a separate regulatory question from the approved Egrifta product itself. If you're sourcing through a compounded route rather than the branded drug, ask directly which pathway your product comes through. Tesamorelin Co works with a provider-reviewed process that connects patients to prescribers and a fulfilling pharmacy partner, rather than compounding or manufacturing anything itself. See tesamorelin cost for what pricing actually looks like across these pathways, and the main tesamorelin overview for the full evidence picture.

How do you calculate the right tesamorelin dose before figuring out timing?

Dose comes before timing in practical terms: you need the right daily amount before deciding exactly when to inject it. The approved product's dosing is based on the phase 3 trial regimen , and reconstitution volume affects how much you draw up per injection. A tesamorelin dosage calculator can help translate a prescribed milligram dose into the right injection volume once you know your reconstitution concentration, which pairs directly with the nightly timing routine described above. Get the concentration and volume right first; the timing habit is simple once the math is settled.

Frequently asked questions

Is it better to take tesamorelin in the morning or at night?

Night is standard. The phase 3 trials used once-daily dosing, and evening administration on an empty stomach matches the body's natural nocturnal GH pulse and avoids food-related blunting of the GHRH response ^[26][24]. There's no head-to-head trial comparing morning versus evening dosing specifically, so the evening recommendation comes from GH physiology, not a dedicated timing study.

How long before a meal should you inject tesamorelin?

Common guidance is at least 30 minutes before eating, since glucose and insulin from a recent meal can blunt the GH pulse tesamorelin is designed to trigger ^[24]. This isn't from a tesamorelin-specific meal-timing trial; it reflects general GH-axis physiology covered in reviews of GHRH analogues.

Do you cycle tesamorelin on and off, or take it continuously?

The approved regimen is continuous daily dosing, studied over a 26-week trial period with an extension phase beyond that ^[26]. There's no validated on/off cycling protocol. Visceral fat reduction appears to reverse after stopping, based on discontinuation data referenced in clinical reviews of tesamorelin ^[10], so intermittent cycling isn't supported by the evidence base.

What happens if you miss a dose of tesamorelin?

No published trial specifically addresses missed-dose handling for tesamorelin. Given its short half-life and once-daily design supported by population pharmacokinetic modeling ^[18], the reasonable approach is to skip the missed dose and resume your regular schedule the next evening, rather than doubling up.

How long does it take to see visceral fat reduction on tesamorelin?

The phase 3 trials that supported approval measured outcomes over a 26-week treatment period ^[26], and that's the timeframe the FDA approval is based on. Individual response varies, and the trials don't establish a specific week-by-week reduction curve, just that meaningful visceral adipose tissue reduction was seen versus placebo by the 26-week mark.

Can tesamorelin be taken by people without HIV?

The FDA approval is specifically for HIV-associated lipodystrophy with excess visceral fat. Use in people without HIV is off-label, and the phase 3 evidence supporting approval doesn't directly generalize to other populations. Off-label use should go through a prescriber who can discuss what evidence does and doesn't exist for your specific situation.

Does tesamorelin need to be refrigerated, and does that affect timing?

Reconstituted tesamorelin requires proper storage and has a limited use window after mixing, which is a separate question from time-of-day dosing. See the tesamorelin reconstitution guide for specific storage and stability details tied to your product's instructions.

Should tesamorelin be taken with food or supplements to boost absorption?

No. Standard guidance is to inject on an empty stomach, roughly 30 minutes before eating, because food (especially carbohydrate) can blunt the GH response the drug is meant to stimulate ^[24]. There's no trial evidence that any supplement improves tesamorelin's effect.

How does tesamorelin's approved use differ from off-label fat-loss use?

The FDA approval covers reduction of excess visceral adipose tissue specifically in HIV-associated lipodystrophy, based on phase 3 trial data ^[26]. General fat-loss or anti-aging use is off-label and not what those trials tested; the approval halo doesn't extend evidence to other populations or goals.

What injection site rotation schedule works with nightly tesamorelin dosing?

Most protocols rotate among abdominal quadrants to reduce the risk of localized skin changes or lipohypertrophy from repeated subcutaneous injections at the same spot. Site rotation doesn't need to align with any particular time of day; it's independent of the evening dosing schedule.

Does tesamorelin interact with GH secretagogues if timing is stacked?

No randomized trial has tested tesamorelin combined with another GH secretagogue on the same schedule. The phase 3 program evaluated tesamorelin as monotherapy ^[26]. Any claimed benefit from stacking is theoretical and should be discussed directly with a prescriber rather than assumed from general GH-axis mechanism arguments.

How long is a typical tesamorelin treatment course before reassessing?

The phase 3 trials assessed a 26-week primary period with a safety extension phase beyond that ^[26]. Many prescribers use a similar window, around six months, before reassessing visceral fat response and deciding whether to continue, though there's no FDA-mandated reassessment interval.

Sources

1. PubMed, Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions (2026): Reviews cataloguing GH-axis peptides including tesamorelin in orthopaedic/sports medicine contexts note limited formal efficacy and safety data outside approved indications
2. PubMed, Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians (2026): Primer describing injectable peptide therapies, including tesamorelin, used off-label in sports medicine settings
3. PubMed, Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (2026): Reviews approved versus unapproved peptide therapies for musculoskeletal and performance goals, noting gaps in safety data for off-label uses
4. PubMed, Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors (2024): Studied tesamorelin efficacy and safety specifically in people with HIV on integrase inhibitor-based antiretroviral regimens
5. PubMed, Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy (2011): Reviews tesamorelin's pharmacology and safety profile in HIV-associated lipodystrophy
6. PubMed, Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy (2012): Discusses visceral fat re-accumulation after tesamorelin discontinuation in HIV-associated lipodystrophy
7. PubMed, Spotlight on tesamorelin in HIV-associated lipodystrophy (2011): Describes tesamorelin's common adverse events including injection site reactions, joint pain, and edema
8. PubMed, Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD (2020): Examines transcriptomic pathways underlying tesamorelin's effect on liver fat in HIV-associated NAFLD
9. PubMed, Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions (2026): Reviews tesamorelin alongside other GH-axis peptides used in metabolic and endocrine contexts, describing it as used as monotherapy in its approved indication
10. PubMed, Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin: meta-analysis of RCTs (2026): Meta-analysis of randomized controlled trials pooling tesamorelin's effects on body composition, hepatic fat, and metabolic outcomes in HIV-associated lipodystrophy
11. PubMed, Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects (2015): Population pharmacokinetic model supporting tesamorelin's once-daily subcutaneous dosing regimen
12. PubMed, Delineating tesamorelin response pathways in HIV-associated NAFLD (2021): Uses proteomic and transcriptomic approaches to map biological response pathways to tesamorelin in NAFLD
13. PubMed, Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: randomised, double-blind trial (2019): Randomized double-blind multicentre trial found tesamorelin reduced hepatic fat fraction in people with HIV and NAFLD
14. PubMed, Tesamorelin, a human growth hormone releasing factor analogue (2009): Describes GHRH analogue mechanism and the physiological blunting of GH release by glucose/insulin after meals
15. PubMed, Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat: pooled phase 3 analysis (2010): Pooled analysis of two multicenter double-blind placebo-controlled phase 3 trials with 26-week treatment period and safety extension data supporting FDA approval
16. eCFR, 21 CFR 216.23, the final 503A Bulks List: Defines the federal bulk drug substance list governing 503A pharmacy compounding
17. eCFR, 21 CFR 216.24, the 503B Bulks List: Defines the federal bulk drug substance list governing 503B outsourcing facility compounding